| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RPRD1B |
| Uniprot No | Q9NQG5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-326aa |
| 氨基酸序列 | MSSFSESALE KKLSELSNSQ QSVQTLSLWL IHHRKHAGPI VSVWHRELRK AKSNRKLTFL YLANDVIQNS KRKGPEFTRE FESVLVDAFS HVAREADEGC KKPLERLLNI WQERSVYGGE FIQQLKLSME DSKSPPPKAT EEKKSLKRTF QQIQEEEDDD YPGSYSPQDP SAGPLLTEEL IKALQDLENA ASGDATVRQK IASLPQEVQD VSLLEKITDK EAAERLSKTV DEACLLLAEY NGRLAAELED RRQLARMLVE YTQNQKDVLS EKEKKLEEYK QKLARVTQVR KELKSHIQSL PDLSLLPNVT GGLAPLPSAG DLFSTD |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RPRD1B重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*RPRD1B promotes tumorigenesis by coordinating transcription of ribosomal proteins and p53*
**作者**：Li H, et al.
**摘要**：研究发现RPRD1B通过调控核糖体蛋白基因和p53的转录协调，促进肿瘤细胞增殖和转移。重组蛋白实验表明其与RNA聚合酶II互作，影响癌症相关通路。
2. **文献名称**：*Structural insights into RPRD1B’s role in transcription termination*
**作者**：Smith J, et al.
**摘要**：通过重组RPRD1B蛋白的晶体结构解析，揭示其与RNA聚合酶II CTD结构域的相互作用机制，提出其在转录终止和RNA加工中的分子功能模型。
3. **文献名称**：*RPRD1B deficiency enhances DNA damage response in breast cancer*
**作者**：Wang Y, et al.
**摘要**：利用重组蛋白技术发现RPRD1B缺失导致乳腺癌细胞DNA损伤应答异常激活，提示其作为基因组稳定性调控因子的潜在治疗靶点价值。
注：以上文献为示例性质，实际发表信息需通过PubMed或Web of Science等平台检索确认。
**Background of RPRD1B Recombinant Protein**
RPRD1B (Regulation of nuclear pre-mRNA domain-containing protein 1B), also known as C20ORF77 or hNAC71. is a conserved eukaryotic protein implicated in transcriptional regulation, RNA processing, and cell cycle control. It interacts with RNA polymerase II and other transcription factors, such as CREB-binding protein (CBP), to modulate gene expression. Structurally, RPRD1B contains N-terminal and C-terminal domains that facilitate protein-protein and protein-RNA interactions, critical for its role in transcriptional elongation and termination.
Recombinant RPRD1B protein is produced using biotechnological methods, often expressed in *E. coli* or mammalian systems, followed by purification via affinity tags (e.g., His-tag). This engineered protein retains functional domains, enabling studies on its molecular mechanisms, such as its involvement in DNA damage response pathways and tumor suppression. Research highlights RPRD1B's dual role in cancer: it acts as a tumor suppressor by stabilizing p53 and promoting apoptosis, yet may exhibit oncogenic properties in certain contexts due to its interaction with cyclin-dependent kinases (CDKs).
Studies using recombinant RPRD1B have advanced understanding of its post-translational modifications (e.g., phosphorylation) and its association with diseases, including breast and colorectal cancers. Its overexpression or mutations correlate with clinical outcomes, suggesting potential as a diagnostic or therapeutic target. Furthermore, recombinant RPRD1B serves as a tool for screening small molecules targeting transcriptional dysregulation in cancer. Despite progress, conflicting evidence about its pro- or anti-tumor effects underscores the need for further research to clarify context-dependent functions. Overall, RPRD1B recombinant protein is a vital resource for dissecting transcriptional regulation and exploring therapeutic strategies in oncology.
×
